Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection

Table 2

Sensitivity, specificity, and positive and negative predictive values of blood serum biomarkers in predicting overall prostate cancer.

	According to Youden’s index					90% sensitivity
	Cut-off	Sensitivity (% (95% CI))	Specificity (% (95% CI))	PPV (% (95% CI))	NPV (% (95% CI))	Cut-off	Specificity (% (95% CI))	PPV (% (95% CI))	NPV (% (95% CI))
tPSA (ng/mL)	4.18	44.6 (35.2-54.3)	62.2 (51.9-71.8)	57.5 (46.4-68.0)	49.6 (40.5-58.8)	2.5	11.2 (5.0-17.5)	53.7 (46.6-60.9)	50.0 (29.1-70.9)
PSAD (ng/mL/cc)	0.09	70.5 (61.2-78.8)	65.3 (55.0-74.6)	69.9 (60.6-78.2)	66.0 (55.7-75.3)	0.05	24.5 (16.4-34.2)	58.0 (50.3-65.3)	70.6 (52.5-84.9)
fPSA (ng/mL)	0.45	37.5 (28.5-47.2)	81.6 (72.5-88.7)	70.0 (56.8-81.2)	53.3 (45.0-61.5)	0.26	3.1 (0.0-6.5)	51.5 (44.5-58.5)	21.4 (0.0-42.9)
%fPSA	11.41	43.8 (34.4-53.4)	89.8 (82.0-95.0)	83.1 (71.0-91.6)	58.3 (50.0-66.2)	7.00	1.0 (0.0-3.0)	50.8 (43.8-57.7)	7.7 (0.0-22.2)
p2PSA (pg/mL)	17.69	17.0 (10.5-25.2)	87.8 (79.6-93.5)	61.3 (42.2-78.2)	48.0 (40.5-55.6)	5.04	1.0 (0.0-3.0)	51.0 (44.1-58.0)	8.3 (0.0-24.0)
%p2PSA	1.77	77.7 (68.8-85.0)	46.9 (36.8-57.3)	62.6 (54.0-70.6)	64.8 (52.5-75.8)	1.41	29.6 (20.8-39.7)	59.4 (51.6-66.9)	72.5 (58.7-86.3)
phi	44.49	56.3 (46.6-65.6)	83.7 (74.8-90.4)	79.7 (69.2-88.0)	62.6 (53.7-70.9)	25.93	23.5 (15.1-31.9)	57.4 (50.1-64.7)	67.6 (51.9-83.4)
PHID	1.04	61.6 (51.9-70.6)	81.6 (72.5-88.7)	79.3 (69.3-87.3)	65.0 (55.9-73.4)	0.54	35.7 (26.3-46.0)	61.8 (53.9-69.3)	77.8 (62.9-88.8)

Abbreviations: CI: confidence interval; free PSA: free prostate-specific antigen; %fPSA: free to total PSA ratio; NPV: negative predictive value; PPV: positive predictive value; PSAD: prostate-specific antigen density; phi: Prostate Health Index; PHID: phi density; tPSA: total PSA; %p2PSA: p2PSA to fPSA ratio.